rs371523347
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3_Moderate
The ENST00000261304.7(GALC):c.206G>A(p.Arg69Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000149 in 1,609,626 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R69G) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000261304.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALC | NM_000153.4 | c.206G>A | p.Arg69Gln | missense_variant | 2/17 | ENST00000261304.7 | NP_000144.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GALC | ENST00000261304.7 | c.206G>A | p.Arg69Gln | missense_variant | 2/17 | 1 | NM_000153.4 | ENSP00000261304 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000593 AC: 9AN: 151834Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000121 AC: 3AN: 248892Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135114
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1457792Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 8AN XY: 725526
GnomAD4 genome AF: 0.0000593 AC: 9AN: 151834Hom.: 0 Cov.: 33 AF XY: 0.0000675 AC XY: 5AN XY: 74126
ClinVar
Submissions by phenotype
Galactosylceramide beta-galactosidase deficiency Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 06, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 10, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 69 of the GALC protein (p.Arg69Gln). This variant is present in population databases (rs371523347, gnomAD 0.004%). This missense change has been observed in individual(s) with a positive newborn screening result for GALC-related disease (PMID: 26795590). This variant is also known as p.R53Q. ClinVar contains an entry for this variant (Variation ID: 550136). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALC protein function with a positive predictive value of 95%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on GALC function (PMID: 27638593). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 15, 2020 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 09, 2022 | Variant summary: GALC c.206G>A (p.Arg69Gln) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 248892 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.206G>A has been reported among 348 infants with low GALC activity referred for genetic testing (Orsini_2016). These reports do not provide unequivocal conclusions about association of the variant with Krabbe Disease. In a functional study, the variant was reported to have slightly reduced GALC activity (around 80% residual activity, Saavedra-Martiz_2016). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 02, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at